121 related articles for article (PubMed ID: 33657977)
1. Inhibition of neovascularisation in human endothelial cells using anti NRP-1 nanobody fused to truncated form of diphtheria toxin as a novel immunotoxin.
Naderi S; Roshan R; Behdani M; Kazemi-Lomedasht F
Immunopharmacol Immunotoxicol; 2021 Apr; 43(2):230-238. PubMed ID: 33657977
[TBL] [Abstract][Full Text] [Related]
2. Selection and characterization of specific nanobody against neuropilin-1 for inhibition of angiogenesis.
Naderi S; Roshan R; Ghaderi H; Behdani M; Mahmoudi S; Habibi-Anbouhi M; Shokrgozar MA; Kazemi-Lomedasht F
Mol Immunol; 2020 Dec; 128():56-63. PubMed ID: 33070092
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapy of angiogenesis using anti-VEGFR2 and anti-NRP-1 nanobodies.
Karami E; Naderi S; Roshan R; Behdani M; Kazemi-Lomedasht F
Cancer Chemother Pharmacol; 2022 Feb; 89(2):165-172. PubMed ID: 34988654
[TBL] [Abstract][Full Text] [Related]
4. A Novel Immunotoxin Targeting Epithelial Cell Adhesion Molecule Using Single Domain Antibody Fused to Diphtheria Toxin.
Roshan R; Naderi S; Behdani M; Ahangari Cohan R; Kazemi-Lomedasht F
Mol Biotechnol; 2023 Apr; 65(4):637-644. PubMed ID: 36129635
[TBL] [Abstract][Full Text] [Related]
5. Production and Conjugation of Truncated Recombinant Diphtheria Toxin to VEGFR-2 Specific Nanobody and Evaluation of its Cytotoxic Effect on PC-3 Cell Line.
Shajari S; Farajollahi MM; Behdani M; Tarighi P
Mol Biotechnol; 2022 Nov; 64(11):1218-1226. PubMed ID: 35478310
[TBL] [Abstract][Full Text] [Related]
6. Production and evaluation of cytotoxic effects of DT386-BR2 fusion protein as a novel anti-cancer agent.
Shafiee F; Rabbani M; Jahanian-Najafabadi A
J Microbiol Methods; 2016 Nov; 130():100-105. PubMed ID: 27609715
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo.
Ramakrishnan S; Olson TA; Bautch VL; Mohanraj D
Cancer Res; 1996 Mar; 56(6):1324-30. PubMed ID: 8640821
[TBL] [Abstract][Full Text] [Related]
8. Second-generation IL-2 receptor-targeted diphtheria fusion toxin exhibits antitumor activity and synergy with anti-PD-1 in melanoma.
Cheung LS; Fu J; Kumar P; Kumar A; Urbanowski ME; Ihms EA; Parveen S; Bullen CK; Patrick GJ; Harrison R; Murphy JR; Pardoll DM; Bishai WR
Proc Natl Acad Sci U S A; 2019 Feb; 116(8):3100-3105. PubMed ID: 30718426
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of angiogenesis and tumour growth by VEGF121-toxin conjugate: differential effect on proliferating endothelial cells.
Wild R; Dhanabal M; Olson TA; Ramakrishnan S
Br J Cancer; 2000 Oct; 83(8):1077-83. PubMed ID: 10993657
[TBL] [Abstract][Full Text] [Related]
10. Carbohydrate-based peptidomimetics targeting neuropilin-1: Synthesis, molecular docking study and in vitro biological activities.
Richard M; Chateau A; Jelsch C; Didierjean C; Manival X; Charron C; Maigret B; Barberi-Heyob M; Chapleur Y; Boura C; Pellegrini-Moïse N
Bioorg Med Chem; 2016 Nov; 24(21):5315-5325. PubMed ID: 27622745
[TBL] [Abstract][Full Text] [Related]
11. Gene therapy of murine solid tumors with T cells transduced with a retroviral vascular endothelial growth factor--immunotoxin target gene.
Jin N; Chen W; Blazar BR; Ramakrishnan S; Vallera DA
Hum Gene Ther; 2002 Mar; 13(4):497-508. PubMed ID: 11874628
[TBL] [Abstract][Full Text] [Related]
12. Development of anti DLL4 Nanobody fused to truncated form of Pseudomonas exotoxin: As a novel immunotoxin to inhibit of cell proliferation and neovascularization.
Mohammadlou M; Salehi S; Baharlou R
Anal Biochem; 2022 Sep; 653():114776. PubMed ID: 35679954
[TBL] [Abstract][Full Text] [Related]
13. Development of a Recombinant Monospecific Anti-PLGF Bivalent Nanobody and Evaluation of it in Angiogenesis Modulation.
Nikooharf A; Arezumand R; Mansouri K; Khoshi AH; Namdar Ahmadabad H
Mol Biotechnol; 2020 Dec; 62(11-12):580-588. PubMed ID: 32975735
[TBL] [Abstract][Full Text] [Related]
14. Effective blocking of neuropilin-1activity using oligoclonal nanobodies targeting different epitopes.
Karami E; Mesbahi Moghaddam M; Behdani M; Kazemi-Lomedasht F
Prep Biochem Biotechnol; 2023; 53(5):523-531. PubMed ID: 35984637
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting angiogenesis with human single-chain variable fragment antibody targeting VEGF.
Hosseini H; Rajabibazl M; Ebrahimizadeh W; Dehbidi GR
Microvasc Res; 2015 Jan; 97():13-8. PubMed ID: 25250517
[TBL] [Abstract][Full Text] [Related]
16. Diphtheria toxin-based anti-human CD19 immunotoxin for targeting human CD19
Zheng Q; Wang Z; Zhang H; Huang Q; Madsen JC; Sachs DH; Huang CA; Wang Z
Mol Oncol; 2017 May; 11(5):584-594. PubMed ID: 28306193
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxicity of a novel fibroblast growth factor receptor targeted immunotoxin on a human ovarian teratocarcinoma cell line.
Zhang H; Zhang S; Zhuang H; Lu F
Cancer Biother Radiopharm; 2006 Aug; 21(4):321-32. PubMed ID: 16999598
[TBL] [Abstract][Full Text] [Related]
18. A nanobody-derived mimotope against VEGF inhibits cancer angiogenesis.
Karami E; Sabatier JM; Behdani M; Irani S; Kazemi-Lomedasht F
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1233-1239. PubMed ID: 32441172
[TBL] [Abstract][Full Text] [Related]
19. Comparison of protein synthesis inhibition kinetics and cell killing induced by immunotoxins.
Sung C; Wilson D; Youle RJ
J Biol Chem; 1991 Aug; 266(22):14159-62. PubMed ID: 1860832
[TBL] [Abstract][Full Text] [Related]
20.
Mousavi A; Sabouri A; Hassanzadeh Eskafi A; Alirahimi E; Kazemi-Lomedasht F; Ghaderi H; Behdani M
Monoclon Antib Immunodiagn Immunother; 2021 Jun; 40(3):113-117. PubMed ID: 34076502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
